We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Asian Journal of Current Research in Clinical Cancer

2024 Volume 4 Issue 1

Computational Assessment of a Series of Twenty Cannabinoid-Based Compounds Targeting the Androgen Receptor and 5α-Reductase Enzyme


, , , ,
  1. Pharmacochemistry Research Laboratory, Faculty of BiologicalChemical Sciences, University Autonomous of Campeche; Humberto Lanz Cárdenas s/n, Ex Hacienda Kalá, C.P. 24085, Campeche, Mexico.

  2. Laboratory of Organic chemistry, Biological Sciences, National Politechnic Institute; Prolongacion de Carpio y Plan de Ayala s/n, Col. Sto Tomas, 11340, Mexico.

  3. Nutrition Laboratory, Faculty of Nutrition, University of Veracruz, Medicos y s/n Odontologos 910210, Unidad del Bosque, Xalapa, Mexico.
Abstract

Several studies have reported that certain cannabinoid derivatives may affect prostate cancer progression. However, their specific actions on the androgen receptor and the 5α-reductase enzyme remain ambiguous, likely due to the structural variability among cannabinoid compounds. This computational investigation aimed to explore the theoretical interactions of 20 distinct cannabinoid derivatives (identified as compounds 1 through 20) with the androgen receptor and the 5α-reductase enzyme, using the protein models 3L3X and 7BW1, respectively. In addition, reference ligands such as testosterone, dihydrotestosterone, flutamide, finasteride, and dutasteride were incorporated as standard molecular tools in the analysis. The findings showed that derivatives 6, 13, 16, and 20 demonstrated superior binding affinity to the androgen receptor in comparison to testosterone, dihydrotestosterone, and flutamide. In addition, the data also indicated that compounds 1, 3, 14, and 18 showed a stronger theoretical interaction with 5α-reductase than dutasteride and finasteride. These results suggest that compounds 6, 13, 16, and 20 may act as potential androgen receptor inhibitors, while derivatives 1, 3, 14, and 18 may act as inhibitors of the 5α-reductase enzyme. These interactions highlight the therapeutic promise of these cannabinoid analogs in the context of prostate cancer management.


How to cite this article
Vancouver
Lopez-Ramos M, FigueroaValverde L, Diaz-Cedillo F, Rosas-Nexticapa M, AlvarezRamirez M. Computational Assessment of a Series of Twenty Cannabinoid-Based Compounds Targeting the Androgen Receptor and 5α-Reductase Enzyme. Asian J Curr Res Clin Cancer. 2024;4(1):40-50. https://doi.org/10.51847/OTi4ctfqwq
APA
Lopez-Ramos, M., FigueroaValverde, L., Diaz-Cedillo, F., Rosas-Nexticapa, M., & AlvarezRamirez, M. (2024). Computational Assessment of a Series of Twenty Cannabinoid-Based Compounds Targeting the Androgen Receptor and 5α-Reductase Enzyme. Asian Journal of Current Research in Clinical Cancer, 4(1), 40-50. https://doi.org/10.51847/OTi4ctfqwq
Articles
Tolerability of Chemoradiotherapy in Geriatric Patients with Pancreatic Cancer
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | İrem Sarıcanbaz
Environmental Impact of the Y-Isomer of HCH: Unveiling Its Role in Cancer Formation
Asian Journal of Current Research in Clinical Cancer
Vol 2 Issue 2, 2022 | Mata Uvaysovna Razhaeva
An Overview of Targeted Therapy Applications in Cancer Treatment
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Yeuan Ting Lee
Exploring Advanced Diagnostic Techniques for Salivary Gland Disorders: A Narrative Overview
Asian Journal of Current Research in Clinical Cancer
Vol 4 Issue 1, 2024 | Chuan Xiang Li
Alternative Perspective on Cancer Based on the Interaction between Plasma Radiation and DNA
Asian Journal of Current Research in Clinical Cancer
Vol 2 Issue 1, 2022 | Mahmoud Mohamed Ahmed
Theoretical Model of Thiophene and Its Derivatives Interaction with BRCA-1
Asian Journal of Current Research in Clinical Cancer
Vol 4 Issue 2, 2024 | Lauro FigueroaValverde
Tolerability of Chemoradiotherapy in Geriatric Patients with Pancreatic Cancer
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | İrem Sarıcanbaz
An Overview of Targeted Therapy Applications in Cancer Treatment
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Yeuan Ting Lee
Evaluating the Effects of Plasma Irradiation and Stevia on Gene Expression and Immune Responses in HepG2 Cells
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Fatma Hussein Abdelwahab
Long-Term Survival Outcomes of Colorectal Cancer Survivors: An In-Depth Exploration
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Zhaobei Cai
Superficial Basal Cell Carcinoma of the Nipple Mimicking Paget’s Disease of the Breast
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Ahmed Samaouel Chehad
Exploring the Radiosensitizing Effects of Tolmetin in Radiotherapy for Human Clonal Cancer Cells
Asian Journal of Current Research in Clinical Cancer
Vol 5 Issue 1, 2025 | Deep Kwatra

About GalaxyPub

Find out more

Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.

Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.